Research Summary

I have performed clinical trials in hematologic malignancies and hematopoietic cell transplantation since 1988. My focus has been predominantly in the acute leukemias and lymphomas, with emphasis on novel chemotherapy drug schedules and dosing aimed at enhancing treatment efficacy and/or reducing treatment toxicity. I discovered the relationship of high-dose cytarabine neurotoxicity and renal insufficiency that led to a dose-modification scheme that reduced neurotoxicity risk (this has become the standard of care in physicians using high doses of cytarabine). I have explored methods of adding immunotherapy to autologous hematopoietic cell transplant, most notably the GVAX platform in AML in conjunction with the Johns Hopkins group. I was the national PI on CALGB protocol 59909 adding rituximab and autologous hematopoietic cell transplant to aggressive chemotherapy for mantle cell lymphoma. I am the UCSF sub-PI on the Ohio State University Blood and Marrow Transplant Research Consortium within the BMT CTN. I am the campus PI on the new University of California Hematologic Malignancies Research Consortium linking UCSF, UCSD, UCD, UCLA, UCSF Fresno and UCI to facilitate clinical and collaborative scientific research in blood cancers in California.

My research activities have been tempered by additional clinical and administrative responsibilities since achieving faculty status. Based on the waxing and waning of nonmalignant hematology faculty at UCSF, I have often had to shift my clinical work to nonmalignant activities (outpatient clinic and inpatient consults) multiple times over my career. At this time, my activities are half malignant and half non-malignant hematology. I served on the National Comprehensive Cancer Network guideline panels for adult acute myeloid leukemia, acute lymphoblastic leukemia, and non-Hodgkin lymphoma.

Education

Olivet College, Olivet, Michigan, B.A., 1978, Chemistry/Biology
University of Michigan Medical School, Ann Arbor, M.D., 1982, Medicine
University of California San Francisco, Residency, 1985, Internal Medicine
University of California San Francisco, Fellowship, 1988, Hematology/Oncology

Honors & Awards

  • 1985
    American Cancer Society Clinical Fellowship Award
  • 2001, 2003
    Faculty teaching award, Division of Hematology-Oncology
  • 2003
    Exceptional Physician Award, UCSF Medical Center
  • 2007
    "Master Clinician" Award, UCSF Department of Medicine

Selected Publications

  1. Trinh TD, Strnad L, Damon L, Dzundza JH, Graff LR, Griffith LM, Hilts-Horeczko A, Olin R, Shenoy S, DeVoe C, Wang L, Rodriguez-Monguio R, Gu TM, Hampton SR, Macapinlac BAC, Yang K, Doernberg SB Reductions in vancomycin and meropenem following the implementation of a febrile neutropenia management algorithm in hospitalized adults: An interrupted time series analysis.  View on PubMed
  2. Valliani S, Ali M, Mahmoo O, Hinduja S, Chen CK, Damon L, Abdulhaq H Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review.  View on PubMed
  3. Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.  View on PubMed
  4. Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation.  View on PubMed
  5. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.  View on PubMed
  6. Burns ST, Damon L, Akagi N, Laszik Z, Ko AH Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.  View on PubMed
  7. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.  View on PubMed
  8. Gupta S, Damon L, Gelfand JM Progressive Neurological Impairment and an Enhancing Brainstem Lesion in a Middle-aged Man.  View on PubMed
  9. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.  View on PubMed
  10. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.  View on PubMed
  11. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with  View on PubMed
  12. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.  View on PubMed
  13. Rahmat LT, Damon LE The Use of Natural Health Products Especially Papaya Leaf Extract and Dandelion Root Extract in Previously Untreated Chronic Myelomonocytic Leukemia.  View on PubMed
  14. Schiller GJ, Damon LE, Coutre SE, Hsu P, Bhat G, Douer D High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial.  View on PubMed
  15. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.  View on PubMed
  16. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.  View on PubMed
  17. Damon LE The use of ibrutinib in chronic lymphocytic leukemia.  View on PubMed
  18. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.  View on PubMed
  19. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission.  View on PubMed
  20. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Douer D, Frankfurt O, Greer JP, Johnson RA, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Rao AV, Shah B, Uy GL, Wang ES, Zelenetz AD, Gregory K, Smith C Acute Lymphoblastic Leukemia, Version 2.2015.  View on PubMed

Go to UCSF Profiles, powered by CTSI